Immune cell therapy with GD2 antibody for neuroblastoma
Part of Cancer clinical trials.
This trial tests a new treatment combining your child's own immune cells (NK cells) with an antibody that targets neuroblastoma cells. It is for children who have just finished standard treatment or whose cancer has come back or not responded, and aims to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 18 years old.
- Your child must have high-risk neuroblastoma that is in maintenance after standard treatment, or has come back after treatment, or has not responded to treatment.
- If the cancer has come back or is not responding, there must be a tumor that can be measured with scans.
- Your child must be generally healthy: blood counts, liver and kidney function, heart function, and lungs must be within acceptable ranges.
- Your child is expected to live at least 6 more months.
- You and your child must agree to participate and sign consent forms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special immune cell treatment (GD2-CAR T cells) for children and teens with neuroblastoma that has come back or not responded to standard therapy. It aims to see if these engineered cells can find and attack the cancer.
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
This early-phase trial tests an immune-cell treatment made from the child’s own cells, designed to attack neuroblastoma. It aims to help children whose cancer has come back or did not respond to standard treatment.
This trial tests a new type of immune therapy (CAR T-cells) that is engineered to find and attack neuroblastoma cells by targeting specific markers (GD2, PSMA, and CD276) on the cancer cells. It is for patients whose cancer has not responded to standard treatments and who are healthy enough to receive this experimental cell therapy.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
This trial tests a special dye (anti-GD2-800CW) that lights up neuroblastoma cells during surgery, helping surgeons see and remove more of the tumor. It is for children with neuroblastoma who are scheduled to have surgery.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.